BABA
Alibaba Group Holding Limited
BABA has slightly lower modeled downside risk, despite its lower overall score.
CCL
Carnival Corporation & plc
CCL has the edge over BABA overall, supported by stronger fundamentals and stronger valuation.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
CCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
CCL's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA has the edge over CCL in the historical PE scenario, which offers more potential upside but is not a forecast.
CCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $24.05 | -18% |
| Forward | 12x | $29.34 | — |
| Current | 13x | $29.34 | — |
| Fair | 14x | $32.52 | +11% |
| Expensive | 21x | $48.32 | +65% |
Historical ranges are pointers, not guarantees.
CCL's PE is in its fair range at 13x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over CCL on the outlook, with more favorable revenue expectations.
CCL Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect CCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA's earnings per share have fallen from their peak: $4.42 over the past year, against $9.27 in mid-2025. Its recent earnings include one-off gains.
CCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.39 | +3.3% |
| Q3 2026 | $2.31 | +17% |
| Q2 2026 | $2.24 | +18% |
| Q1 2026 | $2.27 | +46% |
| Q4 2025 | $2.02 | +40% |
| Q3 2025 | $1.97 | +67% |
| Q2 2025 | $1.90 | +168% |
| Q1 2025 | $1.55 | +384% |
| Q4 2024 | $1.44 | +$1.50 |
CCL has the edge over BABA on earnings, with more consistent year-over-year improvement.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA's revenue has grown year over year for 16 quarters in a row: $40.2B last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA's operating margin was 7.2% last quarter, down 6.9 points from the same quarter a year ago.
CCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.4B | +3.5% |
| Q2 2026 | $6.7B | +5.3% |
| Q1 2026 | $6.2B | +6.1% |
| Q4 2025 | $6.3B | +6.6% |
| Q3 2025 | $8.2B | +3.3% |
| Q2 2025 | $6.3B | +9.5% |
| Q1 2025 | $5.8B | +7.5% |
| Q4 2024 | $5.9B | +10% |
CCL has the edge over BABA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -1.5 points |
| Q2 2026 | 13% | -2 points |
| Q1 2026 | 9.8% | +0.5 points |
| Q4 2025 | 12% | +2.2 points |
| Q3 2025 | 28% | +0.3 points |
| Q2 2025 | 15% | +5.1 points |
| Q1 2025 | 9.3% | +4.2 points |
| Q4 2024 | 9.4% | +2.3 points |
CCL has the edge over BABA on profitability, with a higher operating margin.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
CCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $712M | -3.3% |
| Q2 2026 | $1.8B | +14% |
| Q1 2026 | $697M | +119% |
| Q4 2025 | $12M | -96% |
| Q3 2025 | $736M | +17% |
| Q2 2025 | $1.5B | +114% |
| Q1 2025 | $318M | +$688M |
| Q4 2024 | $319M | +29% |
CCL has the edge over BABA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has 2.4B diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
CCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -20M shares |
| 1 year | -2.4% | -34M shares |
| 3 years | -2% | -28M shares |
| 5 years | +21% | +236M shares |
| Available history | +100% | +684M shares |
CCL has the edge over BABA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $548M |
| Q4 2021 | $94M |
| Q3 2021 | $94M |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over CCL on leverage, with a lower net debt burden relative to earnings.
CCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 4.3x | High |
CCL's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
CCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.6 | Neutral |
| Stochastic | 80.8 | Overbought |
CCL's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA is trading at 21x earnings, a 19% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
CCL PE vs Consumer Cyclical Sector
| Metric | CCL | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 18x | 30% below |
| PE % | 39 | 47 | 8 pts below |
CCL has the edge over BABA on valuation relative to its sector.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
CCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.8 | 9.6% above |
| 20 week MA | $26.3 | 12% above |
| 50 week MA | $27.5 | 6.6% above |
| 100 week MA | $26.6 | 11% above |
| 200 week MA | $21.1 | 39% above |
CCL has the edge over BABA on trend strength, trading above more of its moving averages.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
CCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.3 | $20.8 | -59% |
| 2021 | $20.8 | $21.2 | +1.7% |
| 2022 | $21.2 | $7.81 | -63% |
| 2023 | $7.81 | $18.5 | +137% |
| 2024 | $18.5 | $25.1 | +35% |
| 2025 | $25.1 | $30.7 | +22% |
| 2026 YTD | $30.7 | $29.3 | -4.4% |
CCL has the edge over BABA on returns for 2026, with the stronger performance.